Increasing plant protein sources in the diet modulates gut microbiota and tryptophan metabolism in men at cardiometabolic risk.

Gut MicrobesMay 27, 2026 (epub)
Clinical ResearchGastroenterologyCardiologyOpen access

Gaïa Lépine, Anne-Marie Davila, Gwendal Cueff et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial examined the impact of a flexitarian diet high in plant protein on gut microbiota and tryptophan metabolism in 19 men with cardiometabolic risk. Participants followed two 4-week isoenergetic diets: a flexitarian diet (64% plant protein) and a control diet (36% plant protein). The flexitarian diet led to increased fecal xanthurenic acid and decreased genetic potential for indole production, indicating a shift in tryptophan metabolism.

Key findings

  • FLEX diet reduced taxa associated with animal-based diets, such as Alistipes putredinis.
  • FLEX increased fecal xanthurenic acid compared to the control diet.
  • FLEX decreased the genetic potential for indole production.
  • Changes in microbial composition suggest a shift toward kynurenine and indole propionic acid-related tryptophan pathways.

Why it matters

Understanding how dietary changes influence gut microbiota and metabolism can inform dietary recommendations for individuals at cardiometabolic risk, potentially improving health outcomes through dietary interventions.

Source

Published in Gut Microbes. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.